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Introduction and background
===========================

ST-elevation myocardial infarction (STEMI) has multiple definitions proposed over time and most of them can inclusively be defined as symptoms of ischemia of the myocardium that presents with the classical electrocardiographic change of elevation of ST-segment at J point and positive cardiac biomarkers above the accepted blood level \[[@REF1]\]. Electrocardiographically STEMI can be defined as ST-elevation (STE) of ≥ 1 mm at the J point in 2 contiguous chest and limb leads excluding V2-V3, which must be ≥ 2 mm in men or ≥ 1.5 mm in women \[[@REF2]\].

Major adverse cardiovascular events (MACE) has no concrete definition, but over time various definitions have been used in cardiovascular research with MACE selected as primary or secondary end-point. It has been defined by various authors since mid-1990 to include an overlapping range of adverse events \[[@REF3],[@REF4]\]. Multiple adverse events included in different research as a component of MACE are heart failure, non-fatal re-infarction, recurrent angina pain, re-hospitalization for cardiovascular-related illness, repeat percutaneous coronary intervention (PCI), coronary artery bypass grafting and all-cause mortality \[[@REF5]\]. MACE can also include unscheduled coronary revascularization, stroke, re-infarction and all-cause death and mortality \[[@REF6]\]. MACE with myocardial infarctions have been assessed in the past and multiple articles have been published regarding specific percentage of patients having MACE after particular medical management or after undergoing certain procedures (like PCI) for both STEMI and NSTEMI. The aim of the study is to quantify the available data on the risk of MACE in patients with STEMI irrespective of the mode of management.

Review
======

Method

Literature was searched in PubMed with parallel strategies based on MeSH subheadings and regular keywords for data collection. Table [1](#TAB1){ref-type="table"} shows regular and MeSH keywords for literature search.

###### Regular and MeSH keywords for literature search.

  ----------------------- -------
  Regular keyword-STEMI   
  Total Records           22691
  Records selected        1800
  ----------------------- -------

  ------------------------------------------------------------ ------
  Regular keyword- STEMI Major Adverse Cardiovascular Events   
  Total records                                                1277
  Records selected                                             178
  ------------------------------------------------------------ ------

  ------------------------------------------------ -----
  MeSH Keyword STEMI (Subheading- Complications)   
  Total records                                    276
  Records selected                                 87
  ------------------------------------------------ -----

Studies were selected after applying the following Inclusion/Exclusion Criteria

Inclusion Criteria

1. Human subjects of age 45+ years

2. Diagnosis of STEMI have positive EKG

3. Paper published in English language and within the past 5 years

4. The study types were observational studies, clinical trial including randomized controlled trial, cohort study, case-control study or review article

5. All full papers

Exclusion Criteria

1. Animal Studies

2. Non- English language literature

3. Meta-analysis, case report and case series study

Results

Table [2](#TAB2){ref-type="table"} shows the total number of articles after applying inclusion/exclusion criteria in the following order

###### Total number of articles after applying inclusion/exclusion criteria

  -------------------------- -------
  Regular keyword-STEMI       
  Total Records              22691
  Inclusion/Exclusion         
  Humans                     19128
  English Language           17286
  Published Within 5 years   6066
  Patient Age 45+ years      4518
  Full Text online           1800
  -------------------------- -------

  ------------------------------------------------------------ ------
  Regular keyword- STEMI Major Adverse Cardiovascular Events   
  Total records                                                1277
  Inclusion/Exclusion                                           
  Humans                                                       1074
  English language literature                                  1031
  Published within 5 years                                     529
  Patient age 45+ years                                        455
  Full Text online                                             178
  ------------------------------------------------------------ ------

  ------------------------------------------------------------- -----
  MeSH Search MeSH Keyword STEMI (Subheading - Complications)   
  Total records                                                 276
  Inclusion/Exclusion                                            
  Humans                                                        274
  English language literature                                   259
  Published within 5 years                                      259
  Age 45+ years                                                 216
  Full Text online                                              87
  ------------------------------------------------------------- -----

A total of 1622 articles from keyword search 'STEMI' were excluded due to lack of outcome of interest "Major Adverse Cardiovascular Events" and removal of duplicates. After a refined search, the total number of articles obtained was 178 free full texts. All 178 free full texts were reviewed and 103 were removed due to one of the following reasons:

- Not specifying the disease of interest (those which did not assess for STEMI separately but were rather a composite assessment of STEMI with NSTEMI or ACS as a whole or both)

- Case Report or Case Series Studies (as it only assessed for a particular patient in focus)

- Meta-analysis

- Data Extraction not possible by quality assessment.

 

Finally, 75 publications in PubMed (with free full text available online) were reviewed, which included:

- 51 observational studies, among which one specifically identified itself as a prospective observational study.

- Five studies that identified themselves as RCT and eight other studies that identified themselves as clinical trials \[[@REF7]-[@REF19]\].

- Eight studies identified as Cohort (including two identified as a retrospective cohort and five identified as a prospective cohort) \[[@REF20]-[@REF27]\].

- One study identified as a cross-sectional study (n=1244)

-one as case-control study and

-one as a review article \[[@REF28]-[@REF30]\].

The maximum number of subjects in a study was 15,628 and the minimum was 8, and the total number of subjects included in all 75 studies was 77,782 \[[@REF31],[@REF17]\]. Among all 75 studies, 62 studies explained percutaneous coronary intervention (PCI) either as the intervention of choice or as a primary intervention inclusive of other management strategies. Coronary angiography was explained as the investigation of choice in four studies \[[@REF9],[@REF32]-[@REF34]\].

All the records reviewed were freely available for review and the citations for the borrowed definitions are available. A qualitative review was performed on the available records after Inclusion/Exclusion to include the relevant disease and population with the required outcome.

The figure below shows the flowchart with the process of current literature review (figure [1](#FIG1){ref-type="fig"}).

![Flow chart showing the process of current literature review](cureus-0011-00000005280-i01){#FIG1}

Discussion

The analysis performed was aimed at demonstrating how STEMI was related to MACE irrespective of the management strategy. Though MACE was observed with all the modalities of management for STEMI, the strength of association was not assessed. We firmly believe that there are large variations in the number of MACE events when clearly analyzed for different modalities of treatment. We also found out that MACE incidence depends upon the pre-STEMI health status, age, gender, race, co-morbidities of the patient and many other factors which are not yet explored.

The endpoint of study was major adverse cardiovascular outcome which was explained in the reviewed literature as combination of at least one or more of: all-cause mortality/death (37 studies), re-infarction (25 studies), cardiovascular mortality/death (23 studies), repeat revascularization (18 studies), stroke (16 Studies), heart failure (14 studies), non-fatal re-infarction (11 studies), stent thrombosis (eight studies), major bleeding (seven studies), microvascular obstruction (five studies), re-hospitalization for cardiovascular-related illness (four studies), repeat PCI (four studies), non-cardiovascular mortality/death (two studies) and transient ischemic attack (one study)\[[@REF7]-[@REF45]\].

Table [3](#TAB3){ref-type="table"} summarized some of the studies with MACE reported from selected data for the literature review:

###### Summary of some of the studies with MACE reported from selected data for the literature review.

  -------------------------------------- ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------- ------------------------------------------------------------------------------------------------- ------------------
  Author/ Date                           Study Design                        Population with STEMI                                                                                                                                              Sample Size   Main Points                                                                                       p-value
  Lee et al. \[[@REF35]\],2017           Observational Study                  363 patients with anemia and rest of them with no anemia (between 2005-2014)                                                                                      1751          MACE was 33.8% vs 22.9 % in anemia and non-anemia group respectively                              P\<0.001
  Liu et al. \[[@REF36]\],2015           Observational Study                 Follow up with serum apelin levels for patients who underwent PCI                                                                                                  120           34.3% patients in the low apelin group compared to 13.3% in high apelin group had MACE            N/A
  Li et al. \[[@REF28]\],2017            Multicenter Cross-Sectional Study   607 patients (June 2009 - June 2010) and 637 patients (2015) from hospitals in Northeast China                                                                     1244          No significant change in MACE \[13.34% vs. 13.66%\] in 5 years                                    P = 0.872
  Yu et al. \[[@REF37]\],2017            Observational Study                 Patients who underwent PCI with a mean age of 59.1 years                                                                                                           323           MACCE occurred in 38 patients (12%)                                                               N/A
  Cheng et al. \[[@REF27]\],2014         Cohort Study                        Patients treated with primary PCI followed by measurement of triglyceride (TG)                                                                                     247           The fewer occurrence of MACE with lower TG compared to higher TG levels (26.1% vs. 11.9%)         p = 0.0137
  Grundeken et al. \[[@REF38]\],2017     Observational Study                 Patients with bifurcation (n=123) and non-bifurcation (n=842) lesion undergoing PCI with self-apposing-stents.                                                     965           MACE (8.7% vs. 8.4%) in bifurcation vs. non-bifurcation lesion.                                   N/A
  Reinstadler et al. \[[@REF13]\],2016   Clinical Trial                      792 STEMI patients re-perfused within 12 hrs. of symptom onset followed up for 12 months for MACE which included 540 (68%) patients with antecedent hypertension   792           MACE with hypertensive patient vs non-hypertensive was \[45 patients vs eight patients\]          p-value \<0.01
  Nakashima et al. \[[@REF39]\],2017     Observational Study                 Patients with primary PCI including 212 patients with MI onset in the morning.                                                                                     663           MACE was higher with morning onset of MI compared to other MI onset at other time \[21% vs 4%\]   p=0.012
  Li et al. \[[@REF40]\],2018            Observational Study                 Patients with primary PCI with Drug-Eluting Stent either with Trans-Radial Intervention(TRI) or with Trans Femoral Intervention(TFI)                               689           After propensity score matching the incidence of MACE was TFI \> TRI \[11.6% vs. 4.6%\]           p-value of 0.018
  Park et al. \[[@REF41]\],2016          Observational Study                 Patients with STEMI from INTERSTELLAR STEMI registry who underwent PCI were analyzed for follow up period of 2.2±1.6 years                                         668           MACCE 14.1% (9.7% MACCE and 5.2% all-cause mortality)                                             N/A
  Kołtowski et al. \[[@REF7]\],2016      Randomized Control Trial            Patients from OCEAN trial undergoing PCI with radial (n=52) vs. femoral (n=51) approach.                                                                           103           In radial vs. femoral group \[9.6% vs. 11.8%\]                                                    p=0.48
  Reinstadler et al. \[[@REF42]\],2016   Observational Study                 Patients undergoing primary PCI followed up for specific period.                                                                                                   200           10% suffered MACE.                                                                                p=0.001
  Rajesh et al. \[[@REF44]\],2018        Observational Study                 Follow up for 314 among total patients who underwent PCI with very long Drug Eluting Stent                                                                         343           MACE was observed in 6% patients                                                                  N/A
  Lønborg et al. \[[@REF45]\],2014       Observational Study                 Patient who underwent PCI. ST peak was analyzed for every patient.                                                                                                 942           ST peak was associated with a higher rate of MACE \[26.9% vs. 18.2%\]                             p=0.002
  -------------------------------------- ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------- ------------------------------------------------------------------------------------------------- ------------------

Due to the widespread use of PCI, and least number of papers published with other modes of management as the primary treatment modality for STEMI, the study could not explore much in areas of specific management strategies. MACE occurrence following STEMI is unpredictable, but the rate of occurrence could be minimized with appropriate treatment approach and strategy. More studies are needed to analyze the outcomes of different management strategies in lowering the incidence of MACE. Even with new advanced techniques and technologies, comparisons between the new and old strategies in management should be done in order to find out both long and short-term outcomes.

Conclusions
===========

The objective of our study is to review the relationship between STEMI and major adverse cardiovascular events irrespective of the treatment modality. The current literature review concluded that MACE remains one of the strongest adverse outcomes in STEMI patients. The incidence of MACE ranges from 4.2% to 51% irrespective of the mode of treatment, with follow-up visits ranging from day 0 to 10 years following STEMI. The current literature review has some limitations: the study limits its analysis in terms of age (patients involved were ≥45 years old), gender (no gender-specific analysis was performed), modality of treatment, duration of follow up (none of the literature explained the long term follow up ≥10 years) and many other unexplored factors which can be tested in future studies.
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